Alembic Pharmaceuticals has received USFDA approval for Azelastine Hydrochloride Ophthalmic Solution used for the treatment of allergic conjunctivitis. The drug is equivalent of Optivar Ophthalmic […]
Alembic Pharmaceuticals has received final USFDA approval for Acetazolamide extended-release capsules, used for the treatment of various kinds of glaucoma. The drug is therapeutically equivalent […]
Alembic Pharmaceuticals has received final USFDA approval for Pramipexole Dihydrochloride extended-release tablets used for the treatment of Parkinson’s disease. The drug will be marketed in […]
Alembic Pharmaceuticals has raised ₹3500 million through allotment of non-convertible debentures (NCDs) on private placement basis. The NCD committee of Alembic Pharmaceuticals Ltd has allotted […]
Alembic Pharmaceuticals has received USFDA approval for Temazepam capsules which is used for the treatment of insomnia. The drug will be made available in strengths […]
Alembic Pharmaceuticals has received USFDA approval for Olopatadine Hydrochloride ophthalmic solution, used to treat allergic conjunctivitis. The approved product is therapeutically equivalent to the reference […]
Alembic Pharma has received USFDA approval for its Acyclovir ointment USP, used for the treatment of genital herpes. The ointment is therapeutically equivalent to the […]
Alembic Pharmaceuticals has acquired a US based generic drug developer West Caldwell, New Jersey. With this acquisition Alembic will now have a total of 69 […]
Alembic Pharmaceuticals has received the final USFDA approval for Abbreviated New Drug Application (ANDA) of anti-bacterial Doxycycline capsules USP 75 mg and 100 mg. The […]
Alembic Pharmaceuticals has received final USFDA approval for Fenofibric acid delayed-release capsules used for lowering high cholesterol and increasing good cholesterol. The approved product is […]
Copyright © 2025 | WordPress Theme by MH Themes